Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…prevent malnutrition in elderly adults. Novel therapies such as resmetirom and glucagon-like peptide-1 receptor agonists show promising ef…
…tients to receive new SGLT2i (RR 0.59, 95% CI 0.42 to 0.82) and GLP-1RA (RR 0.62, 95% CI 0.49 to 0.79) prescriptions; Hispanic patients…
…quency (episodes per person or per unit time, as reported). (4) Insulin dosage: we extracted total daily dose (TDD) and weight-normaliz…
…The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual gut hormone therapies has revolutionised obesity trea…
…gue that prescribing Glucagon-like peptide-1 receptor agonists (GLP-1) for weight loss is ethically justified on grounds of autonomy,…
…cial in these patients. Remarkably, the benefits of GLP-1RA and SGLT2i are independent of type 2 diabetes status or baseline renal fun…
…These findings extend safety observations beyond semaglutide to tirzepatide. Healthcare providers should consider this potential risk when …
…ient, with ICERs generally below willingness-to-pay thresholds. Dapagliflozin was cost saving in type 2 diabetes (T2D) in the United Kingdom …
…re fasted for 12 hours and then intraperitoneally injected with streptozotocin at 40 mg/kg for five consecutive days. Control mice received eq…
…ficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity, overweight, pre-diab…
…hese neurohumoral pathways, most notably with beta-blockers and ACE inhibitors. At present, HF is defined as ‘a clinical syndrome with signs a…
…ristics and outcomes of patients with T2D and CKD who initiated SGLT2i or GLP-1 RA in China. The results are important for understandi…